Allergy Immunotherapies Market By Type (Subcutaneous Immunotherapy and Sublingual Immunotherapy), By Application (Allergic Rhinitis, Allergic Asthma, and Other), Industry Trends, Estimation & Forecast, 2023-2030

Market Overview

Immunotherapy is a treatment for allergic reactions to substances such as grass pollens, house dust mites and bee venom. Immunotherapy reduces inflammation that characterizes rhinitis and asthma. The incremental increases of allergen cause the immune system less sensitive to the substance, causing a blocking antibody, that reduces the symptoms of allergy when the substance is encountered in the future. Allergy Immunotherapies are two types subcutaneous immunotherapy, and sublingual immunotherapy. Subcutaneous immunotherapy (SCIT), are also known as Allergy shots, are the most commonly used and most effective form of allergy immunotherapy. Sublingual immunotherapy (SLIT) are in the form of allergy tablets. It reduces symptoms by helping the body build resistance to the effects of an allergen.

The Allergy Immunotherapies market was valued at 2088.2 million US$ in 2022 and is projected to reach 4191.5 million US$ by 2030, at a CAGR of 9.1% during the forecast period.

Market Dynamics

Rising prevalence of various types of Allergies is a key driving factor of the market. For instance, according to Asthma and Allergy Foundation of America, Allergic rhinitis is common in Europe and Australasia. According to World Health Organization, in 2017, an estimated number of people worldwide with asthma, linked to allergies, is approximately 235 million. According to World Allergy Organisation (WAO), an estimate of allergy prevalence of the global population by country ranges between 10 – 40%. In 2017, around 150 million Europeans suffered from chronic allergic diseases, and it is estimated that by 2025 half of Europe population will suffer from chronic allergic diseases. According to the European Academy of Allergy and Clinical Immunology (EAACI), Allergic diseases is expected to reach 4 billion in 2050. However, Lack of awareness about allergies and its treatments might hamper the market growth. For instance, In Europe, 49% of people are not aware of their food allergies and are undiagnosed due to the shortage of medical specialists. Increasing regulatory approvals for allergy immunotherapy would provide lucrative opportunities for the market in the coming years.

Market Segmentation

The global Allergy Immunotherapies market is mainly classified based on Type, Application. Type is further segmented into Subcutaneous Immunotherapy, Sublingual Immunotherapy. Subcutaneous Immunotherapy is dominating the global Allergy Immunotherapies market, due to the increasing clinical study of Subcutaneous Immunotherapy for allergy. For instance, Ragweed sublingual immunotherapy (SLIT) has received the U.S FDA approval in 2014 for adults with ragweed allergies. The sublingual immunotherapy is in the phase III study for kids Seasonal allergy. The commercialization of new Subcutaneous Immunotherapy is boosting the market. For instance, AllergyEasy has introduced Sublingual Immunotherapy for Nut Allergy Treatment. By Application, the market is further divided into Allergic Rhinitis, Allergic Asthma, Other.

Regional Analysis

Based on geography, the global Allergy Immunotherapies market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America is showing significant growth for global Allergy Immunotherapies market, due to the increasing prevalence of Allergy. For instance, Allergies are the 6th leading cause of chronic illness in the U.S. According to National Center for Health Statistics, around 60 million Americans suffer from allergic rhinitis, and this number is increasing each year. 30% of adults and 40% of children suffer from allergies. In 2018, 5.2 million suffer from allergic rhinitis in the U.S.

Competitive landscape

Key players operating in the Allergy Immunotherapies industry include ALK-Abello, Allergy Therapeutics, Circassia, DBV Technologies., HAL, Holister Stier, Leti, Merck KGaA (Allergopharma), Stallergenes Greer, Anergis S.A.

Commercialization of new Allergy Immunotherapies, studies on drugs for allergy, and increasing regulatory approval are boosting the global Allergy Immunotherapies market.

Allergy Immunotherapies Market Segmentation

By Type
• Subcutaneous Immunotherapy
• Sublingual Immunotherapy

By Application
• Allergic Rhinitis
• Allergic Asthma
• Other
 
By Geography
• North America
o The U.S.
o Canada
o Mexico
• Europe
o U.K
o Germany
o France
o Italy
o Rest of Europe
• Asia Pacific
o India
o China
o Japan
o South Korea
o Rest of Asia Pacific
• South America
o Brazil
o Argentina
o Rest of South America
• Middle East & Africa
o GCC Countries
o Egypt
o South Africa
o Rest of Middle East & Africa

Allergy Immunotherapies Market Key Players

• ALK-Abello
• Allergy Therapeutics
• Circassia
• DBV Technologies.
• HAL
• Holister Stier
• Leti
• Merck KGaA (Allergopharma)
• Stallergenes Greer
• Anergis S.A.

Table of Content

1. Market Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. Market Scope

2. Research Methodology
2.1. Primary Research
2.2. Research Methodology
2.3. Assumptions & Exclusions
2.4. Secondary data sources

3. Allergy Immunotherapies Market Overview
3.1. Report Segmentation & Scope
3.2. Key Market Trend
3.3. Drivers
3.3.1. Increasing prevalence of various types of Allergies
3.4. Restraints
3.4.1. Lack of awareness about allergies and its treatments
3.5. Opportunity
3.5.1. Increasing regulatory approvals for allergy immunotherapy
3.6. Porter’s Five Forces Analysis
3.6.1. Porter’s Five Forces Analysis
3.7. Market Share Analysis

4. Type Overview
4.1. Introduction
4.1.1. Market Size & Forecast
4.2. Subcutaneous Immunotherapy
4.2.1. Market Size & Forecast
4.3. Sublingual Immunotherapy
4.3.1. Market Size & Forecast

5. Application Overview
5.1. Introduction
5.1.1. Market Size & Forecast
5.2. Allergic Rhinitis
5.2.1. Market Size & Forecast
5.3. Allergic Asthma
5.3.1. Market Size & Forecast
5.4. Other
5.4.1. Market Size & Forecast

6. Allergy Immunotherapies Market Regional Overview
6.1. Introduction
6.1.1. Market Size & Forecast
6.2. North America Allergy Immunotherapies Market
6.2.1. North America Market Size & Forecast, By Country
6.2.2. North America Market Size & Forecast, By Type
6.2.3. North America Market Size & Forecast, By Application
6.2.4. The U.S.
6.2.4.1. Market Size and Forecast
6.2.5. Canada
6.2.5.1. Market Size and Forecast
6.2.6. Mexico
6.2.6.1. Market Size and Forecast
6.3. Europe Allergy Immunotherapies Market
6.3.1. Europe Market Size & Forecast, By Country
6.3.2. Europe Market Size & Forecast, By Type
6.3.3. Europe Market Size & Forecast, By Application
6.3.4. Germany
6.3.4.1. Market Size and Forecast
6.3.5. France
6.3.5.1. Market Size and Forecast
6.3.6. UK
6.3.6.1. Market Size and Forecast
6.3.7. Italy
6.3.7.1. Market Size and Forecast
6.3.8. Spain
6.3.8.1. Market Size and Forecast
6.3.9. Rest of Europe
6.3.9.1. Market Size and Forecast
6.4. Asia-Pacific Allergy Immunotherapies Market
6.4.1. Asia-Pacific Market Size & Forecast, By Country
6.4.2. Asia-Pacific Market Size & Forecast, By Type
6.4.3. Asia-Pacific Market Size & Forecast, By Application
6.4.4. Japan
6.4.4.1. Market Size and Forecast
6.4.5. China
6.4.5.1. Market Size and Forecast
6.4.6. Australia
6.4.6.1. Market Size and Forecast
6.4.7. India
6.4.7.1. Market Size and Forecast
6.4.8. South Korea
6.4.8.1. Market Size and Forecast
6.4.9. Rest of Asia-Pacific
6.4.9.1. Market Size and Forecast
6.5. South America Allergy Immunotherapies Market
6.5.1. South America Market Size & Forecast, By Country
6.5.2. South America Market Size & Forecast, By Type
6.5.3. South America Market Size & Forecast, By Application
6.5.4. Brazil
6.5.4.1. Market Size and Forecast
6.5.5. Argentina
6.5.5.1. Market Size and Forecast
6.5.6. Rest of South America
6.5.6.1. Market Size and Forecast
6.6. Middle East & Africa Allergy Immunotherapies Market
6.6.1. Middle East & Africa Market Size & Forecast, By Country
6.6.2. Middle East & Africa Market Size & Forecast, By Type
6.6.3. Middle East & Africa Market Size & Forecast, By Application
6.6.4. GCC Countries
6.6.4.1. Market Size and Forecast
6.6.5. Egypt
6.6.5.1. Market Size and Forecast
6.6.6. South Africa
6.6.6.1. Market Size and Forecast
6.6.7. Rest of Middle East & Africa
6.6.7.1. Market Size and Forecast

7. Company Profile
7.1. ALK-Abello
7.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2. ALK-Abello Product Category, Application, and Specification
7.1.3. ALK-Abello Financial Performance (2016-2018)
7.1.4. Main Business/Business Overview
7.2. Allergy Therapeutics
7.3. Circassia
7.4. DBV Technologies.
7.5. HAL
7.6. Holister Stier
7.7. Leti
7.8. Merck KGaA (Allergopharma)
7.9. Stallergenes Greer
7.10. Anergis S.A.